HAS2 and polycystic ovary syndrome: These results indicate that the expression of follicular markers, i.e., Bmp (Figure 4B), Cyp11a1 (Figure 4C), and Has2 (Figure 4D), was upregulated by EC500 treatment and may therefore be involved in improvement of follicular development in rats with letrozole-induced PCOS during the ovarian cycle (Epifano and Dean, 2002).